Lord, Abbett & Co
CDTX

Lord, Abbett & Co’s Cidara Therapeutics CDTX Stock Holding History

Lord, Abbett & Co’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-109,704
Closed -$10.5M – 559
2025
Q3 		$10.5M Buy
+109,704
New +$7M 0.03% 369

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Lord, Abbett & Co's CDTX Position: Q4 2025 in Review

Lord, Abbett & Co sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 109,704 shares — an estimated $10.5M sold.

Lord, Abbett & Co first reported a position in CDTX in Q3 2025 and held it in 1 quarter. The position peaked at $10.5M in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

  • Lord, Abbett & Co reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 109,704 Cidara Therapeutics shares in Q4 2025, an estimated $10.5M.
  • Lord, Abbett & Co first reported a position in Cidara Therapeutics in Q3 2025 and held it in 1 quarter.
  • Lord, Abbett & Co's Cidara Therapeutics position peaked at $10.5M in Q3 2025.
  • 255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on Lord, Abbett & Co's 13F filing for Q4 2025, filed 13 Feb 2026.